Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Louis J. Aronne(Cornell University), Julia P. Dunn(Eli Lilly (United States)), Çağrı Şenyücel(Eli Lilly (United States)), Clare J. Lee(Eli Lilly (United States)), Elisa Gomez Valderas(Eli Lilly (United States)), Deborah B. Horn(The University of Texas Health Science Center at Houston), Wayne Ho(University of California, Los Angeles), Carel W. le Roux(University College Dublin), Leonard C. Glass(Eli Lilly (United States)), Beverly L. Falcón(University of California, San Francisco)
Cited by 411
Related Papers
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
|New England Journal of Medicine|2015|2.6k
Inhibition of Food Intake in Obese Subjects by Peptide YY<sub>3–36</sub>
|New England Journal of Medicine|2003|1.6k
Definition and diagnostic criteria of clinical obesity
|The Lancet Diabetes & Endocrinology|2025|1.3k
Joint international consensus statement for ending stigma of obesity
|Nature Medicine|2020|1.1k
Morbidity and mortality associated with obesity
|Annals of Translational Medicine|2017|1k